Publications View key publications by GEMINI investigators. If you are interested in joining or partnering with GEMINI, please contact us.

Comprehensive molecular characterization of gastric adenocarcinoma

Nature. 2014 Sep 11;513(7517):202-9.

Integrated molecular description of gastric cancer. Mutations, copy-number changes and translocations for select genes are shown across samples classified by molecular subtype.


Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett's-like metaplasia

Cancer Cell. 2012 Jan 17; 21(1): 36-51.

Representative images of human and mouse squamocolumnar junction (SCJ), Barrett Esophagus and Esophageal Adenocarcinoma tissue stained for Doublecortin like kinase-1 (Dckl1).


The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Nature. 2021 Dec;600(7890):727-730.

Best percentage change from baseline in the size of target lesions among participants in the efficacy population.

  1. Pembrolizumab group.
  2. Placebo group.
    Only those participants in the efficacy population who had RECIST-measurable disease at baseline and at least one evaluable post-baseline measurement are evaluable for change from baseline (n=124 in the pembrolizumab group, n=122 in the placebo group). The treatment regimen included trastuzumab and chemotherapy in both groups. Increases from baseline greater than 100% were truncated at 100%.

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

JAMA Oncol. 2021 Jun 1;7(6):895-902.

Overall survival of patients with microsatellite instability advanced gastric or gastroesophageal junction cancer after treatment with chemotherapy, pembrolizumab, or a combination.